Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer
Open Access
- 18 October 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 94 (12), 1468-1476
- https://doi.org/10.1002/bjs.5996
Abstract
Background: This prospective randomized study compared the survival of patients with tumour node metastasis (TNM) stage T2 N1–2 gastric cancer treated by gastrectomy alone or gastrectomy followed by uracil–tegafur. Methods: Patients were randomly assigned to surgery alone or to surgery and postoperative uracil–tegafur 360 mg per m2 per day orally for 16 months. The primary endpoint was overall survival. Relapse-free survival and site of recurrence were secondary endpoints. Results: Of 190 registered patients, 95 were randomized to each group; two patients with early cancer were subsequently excluded from the chemotherapy group. The trial was terminated before the target number of patients was reached because accrual was slower than expected. Drug-related adverse effects were mild, with no treatment-related deaths. At a median follow-up of 6·2 years, overall and relapse-free survival rates were significantly higher in the chemotherapy group (hazard ratio for overall survival 0·48, P = 0·017; hazard ratio for relapse-free survival 0·44, P = 0·005), confirming the survival benefit shown in an interim analysis performed 2 years earlier. Conclusion: Interim and final analyses revealed a significant survival benefit for postoperative adjuvant chemotherapy with uracil–tegafur in patients with serosa-negative, node-positive gastric cancer. Registration number: NCT00152243 (http://www.clinicaltrials.gov).Keywords
Funding Information
- Japan Health Sciences Foundation
- Taiho Pharmaceutical Company
This publication has 33 references indexed in Scilit:
- de Gramont schedule is a very low toxic and effective regimen in low performance status patients affected by metastatic gastric cancer: preliminary report.Tumori Journal, 2002
- A Systematic Overview of Chemotherapy Effects in Gastric CancerActa Oncologica, 2001
- Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trialsAnnals of Oncology, 2000
- Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trialsEuropean Journal of Cancer, 1999
- Success of Adjuvant Chemotherapy Trials for Gastric CancerPublished by Springer Science and Business Media LLC ,1999
- Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.Journal of Clinical Oncology, 1993
- A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim reportBritish Journal of Cancer, 1989
- Mitomycin C as an Adjuvant in Resected Gastric CancerAnnals of Surgery, 1983
- An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British stomach cancer groupWorld Journal of Surgery, 1983
- Gastric carcinoma treated by chemotherapy after resection: A controlled studyThe American Journal of Surgery, 1980